Pharmaceuticals - San Francisco, California, United States
Glycyx has a simple premise: impaired gut function causes systemic inflammation, which accelerates disease progression and mortality in many severe illnesses. Our lead is a novel oral, small molecule, immune potentiator. The target pathway has complementary mechanisms in oncology, with direct tumor effects, and broad activity across multiple immune cell types. Our lead compound has previous Phase 2b data with effective target engagement and good safety and tolerability.
Gmail
Varnish
Wix
Mobile Friendly
Google Cloud Hosting